This page exists because a search pairing exists. The strings mk677 and chemyo appear together in queries often enough that the pairing has a life of its own, and a reader arriving through it deserves a note that says what each token refers to rather than a note that pretends the pairing is a statement. The compound is the object of published literature: mk-677, also written mk677, known in pharmacology as ibutamoren, is described in the indexed record as a growth hormone secretagogue and as an agonist at the ghrelin receptor. The vendor token belongs to a different layer entirely, the layer of public claims about companies, which this site files and does not evaluate. The two are described here side by side and not joined.
I want the boundary stated before any detail, because it determines what the rest of the page can say. I describe the compound as literature describes it, with receptor-level, cell and animal findings carrying their context labels, and findings in cell or animal studies may not translate to human outcomes. I state no dose for any person, give no cycle structure and give no administration or injection guidance. As for the pairing, I do not assert that any company offers anything and I do not assert that any company does not, because a query string cannot support either sentence. The column index is the research compound literature notes and the shared name material is at chemyo peptides.
what the compound is, as the literature describes it
In the published record the compound is characterised at the receptor first. It is described as an agonist at the ghrelin receptor, which the older literature calls the growth hormone secretagogue receptor, and as a growth hormone secretagogue, meaning a compound studied for its effect on the secretory axis that releases growth hormone. It is also described as a non-peptide small molecule that is orally active, which is a genuine chemical distinction from the peptide secretagogues that dominate the surrounding subject area and the reason it turns up in searches that otherwise concern peptides. Ibutamoren is the name used in much of the pharmacology literature, and the forms mk-677 and mk677 are the ones that circulate in public text.
From that receptor description the literature moves outward through model systems, and each system carries its own ceiling. Receptor-level work characterises binding and signalling in expressed preparations. Cell work looks at downstream responses in cultured cells exposed to the compound under controlled conditions. Animal work measures endocrine and body-composition endpoints in a specified species over a stated duration. Controlled studies in defined human populations also appear in the record, and what this page says about them is limited to what they were designed to measure. A result in a receptor assay is a result about that assay, and findings in cell or animal studies may not translate to human outcomes.
where the vendor token sits, and why the pairing is not a claim
The two tokens belong to different layers and behave differently under inspection. The compound token is the object of literature: it has receptor pharmacology, model systems, defined endpoints and a record that can be read, argued about and summarised. The vendor token is the object of a claim layer, which is to say the layer of things people say in public about companies. This site files that layer and does not evaluate it, because evaluating it would require a sealed lot, a documented chain of custody and accredited analysis tied to that lot. A search box supplies none of those, so the vendor token stays here as a token and never becomes a finding.
What can be said about the pairing is narrow but real: the two strings co-occur in queries, the co-occurrence has circulated long enough to be suggested by autocomplete, and the queries formed that way land on pages that then have to explain the mismatch. That is a fact about search behaviour. It is not a fact about a compound, not a fact about a company, and not the faintest evidence of any relationship between the two. The table below separates what each token can carry so the difference stays visible instead of dissolving into a single sentence that sounds like it means something.
| token | which layer it belongs to | what it can support |
|---|---|---|
| mk677 | the literature layer: receptor pharmacology, cell and animal work, controlled studies | supports statements about what published work measured in a named system |
| chemyo | the claim layer: public talk about a company, filed here as anecdote | supports statements that people wrote things; no verdict is offered on any company |
| the pairing in a query | search behaviour: co-occurrence of two strings typed together | shows how tokens travel in search; supports no relationship between them |
| autocomplete suggestion | a ranking output generated from aggregate query behaviour | shows that a phrasing is common, not that it is meaningful |
| a page title repeating both | a document optimised for that query shape | shows that a page targets the query, not that the page verifies anything |
how this page reads literature, and what it refuses
The reading rule is that a finding and its context arrive together. Every statement about the compound in this note is tied to the system it came from: receptor preparation, cell line, animal model, or controlled study in a defined population. When the record is mixed, as it is on several endocrine endpoints, I write that it is mixed rather than averaging it into a confident sentence, because conflicting measurements under different protocols are the actual state of the record and smoothing them would misrepresent it. Where a question about the compound is really a question about hormones, it belongs to the testosterone literature review, and where it is a question about compartments, it belongs to the body composition research overview.
The refusals are short and they are not negotiable. This page states no dose for any person, offers no cycle structure, gives no administration or injection guidance, and states no outcome for any reader. Community talk about the compound is filed as anecdotal user reports, which are evidence that people wrote things and not evidence about the compound, and it is kept in its own category rather than used to fill gaps in the literature. For the background chemistry that makes sense of the surrounding field, peptide chemistry basics sits in another column, and public discussion of the name is archived at reddit discussion notes.
- A receptor-level finding describes that preparation; a cell finding describes that line; an animal finding describes that model.
- Findings in cell or animal studies may not translate to human outcomes, and no outcome for any person is stated here.
- This page states no dose for any person and gives no cycle, administration or injection guidance.
- The vendor token belongs to a claim layer that is filed and not evaluated, on either side of the question.
- Community shorthand is anecdote, kept separate from indexed literature and never used to settle a literature question.
Frequently asked questions
Is mk-677 the same thing as ibutamoren?
Does this page say anything about chemyo?
What does the literature actually measure for this compound?
Do you provide a dose, a cycle or administration guidance?
Does this page list prices, discounts, coupons, shipping, payment or refund details?
References and public sources
Literature searches and public reference links. None of them confirms or denies any community claim filed elsewhere on this site.
- pubmed - ibutamoren growth hormone secretagogue
- pubmed - mk-677 ghrelin receptor agonist characterisation
- ncbi - non-peptide secretagogue receptor pharmacology
- ncbi - animal to human translation limits in endocrine research
- scholar google - compound identifier and naming variation in search
- wikipedia - growth hormone secretagogue
- wikipedia - ghrelin